Yes I can agree on those numbers. I'am just being very very concervative on the patient population penetration rate ( based on 9M USA, 100M Worldwide) and the cost per patient to show how easy it will be to generate $1B in top-line sales for just ENDO. The cost to treat ENDO in the USA alone is $20B on an annual basis.
The Elagolix partnership is going to be a significant game changer for NBIX. I don't think most investors have realized that. IMO, NBIX moves from a tier 4 biotech Co a Tier 2 co and tier 1 apon Elagolix FDA approval in Q4 FY13/ Q1 FY14. Than a follow on indication in FY15 for Uterin F.